LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products.
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.